clinical trial · NCT07217587
Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis
Janssen Research & Development, LLC·phase3·recruiting·n = 115
Myasthenia GravisNipocalimabEfgartigimod
brief summary
The purpose of this study is to assess how well nipocalimab works when compared to efgartigimod in participants with generalized myasthenia gravis (a condition in which body's immune system mistakenly attacks and damages the connection between nerves and muscles causing muscle weakness).
started
Jan 5, 2026
primary completion
Sep 28, 2027
completion
Dec 11, 2028
last updated
Apr 13, 2026
official title
Efficacy and Safety of Nipocalimab vs Efgartigimod for Patients With Generalized Myasthenia Gravis in a Randomized, Open-label, Phase 3b, Interventional Trial Including Within Class Switching From Efgartigimod to Nipocalimab
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol